|
Elvucitabine
(ACH-126,443, or Beta-L-Fd4C)
Also
known as ACH-126443, L-Fd4C or beta-L-Fd4C, elvucitabine
is a NRTI currently under investigation for the treatment
of HIV infection and chronic hepatitis B.
In addition to its anti-HIV effects, elvucitabine has
potent anti-HBV activity in laboratory studies. A Phase
I/II study of elvucitabine in patients with chronic
HBV infection demonstrated acceptable pharmacokinetics
and safety. Phase II studies of elvucitabine in HBV-infected
patients are underway.
Newer Anti-HIV
Drugs and How to Use Them: Part I
6/23/09
Experimental
NRTI Elvucitabine
Suppresses HIV as well as Lamivudine at 48 Weeks
11/07/08
|
